Zoetis Inc. or Genmab A/S: Who Invests More in Innovation?

Innovation Investment: A Comparative Analysis

In the ever-evolving landscape of pharmaceuticals, innovation is the key to staying ahead. Over the past decade, Genmab A/S and Zoetis Inc. have demonstrated contrasting approaches to research and development (R&D) investments. From 2014 to 2023, Genmab A/S has consistently outpaced Zoetis Inc. in R&D spending, with a staggering 1,200% increase, reaching a peak in 2023. In contrast, Zoetis Inc. has shown a steady yet modest growth of around 55% in the same period.

Genmab A/S's commitment to innovation is evident, with its R&D expenses growing from approximately 500 million in 2014 to over 7.6 billion by 2023. This strategic focus on R&D underscores Genmab's dedication to pioneering new treatments. Meanwhile, Zoetis Inc., while more conservative, has maintained a consistent investment in innovation, reflecting its stable approach to growth in the animal health sector.